Vicki Moore is a contributing writer at Hematology Advisor. With a PhD in biology from Arizona State University, Vicki specializes in medical writing with a focus on hematology and oncology, while also exploring topics such as immunotherapy, palliative care, and public health. Her work has been featured in various reputable outlets, including Infectious Disease Advisor, NewsBreak, and Oncology Nurse Advisor.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Vicki Moore's coverage primarily focuses on citing data in the healthcare and pharmaceutical space, with an emphasis on oncology research, cancer treatments, patient preferences, treatment outcomes, and medical advancements. Given her focus on citing data extensively, she would likely be interested in pitches that provide access to or insights from new studies or clinical trials related to these topics.
She seems dedicated to providing factual information backed by solid evidence. Therefore, sources reaching out should have credible expertise in their respective fields and be able to offer scientific backing for any claims made.
Vicki does not seem to maintain a specific geographic focus but instead appears focused on incorporating the most recent findings within the healthcare and pharmaceutical domain regardless of location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Vicki Moore
A phase 2a study revealed that treatment with sapablursen appeared generally safe and well-tolerated in patients with non-transfusion-dependent β-thalassemia intermedia (NTDT), but it did not significantly increase blood hemoglobin or reduce liver iron content (LIC). These results were reported in the journal Blood Advances.
By: Vicki Moore
Women with germline TP53 pathogenic sequence variants (PSVs), such as those involved in the hereditary Li-Fraumeni syndrome (LFS), may desire guidance on reproductive and hormonal health, but evidence-based recommendations are limited. This is according to a review in the journal The Oncologist, authored by researchers at Tel-Aviv University and Sheba Medical Center in Israel.
By: Vicki Moore
| Publish Date The addition of metformin to neoadjuvant chemotherapy for patients with locally advanced or metastatic breast cancer
By: Vicki Moore
| Publish Date A final analysis of the addition of atezolizumab to standard care in recurrent ovarian cancer has shown a “clinically
By: Vicki Moore
For children with pediatric B-cell acute lymphoblastic leukemia (B-ALL) at very high-risk first relapse, a phase 2 study evaluating inotuzumab ozogamicin met its primary endpoint. Study findings were reported in the journal Lancet Haematology.
By: Vicki Moore
Li C, Xu J, Chen R, Lin Y. Machine learning-based prediction of overall survival in non-metastatic renal cell carcinoma after radical nephrectomy Sci Rep . Published online July 13, 2026. doi:10.1038/s41598-026-61401-0
By: Vicki Moore
| Publish Date In patients with type 2 diabetes mellitus who undergo radical nephrectomy for renal cell carcinoma (RCC), the use of
By: Vicki Moore
| Publish Date An emerging RNA-based blood test for biennial breast cancer screening of women with dense breasts may be more
By: Vicki Moore
| Publish Date For women with newly diagnosed invasive breast cancer or high-grade ductal carcinoma in situ (DCIS), early identification
By: Vicki Moore
| Publish Date Adding irinotecan to standard-of-care (SOC) chemoradiotherapy does not improve outcomes in patients with MRI-defined, locally
